ZA200710341B - Alpha-(aryl-or heteroaryl-methyl)beta-piperidinopropanoic acid compounds as ORL 1-receptor antagonists - Google Patents
Alpha-(aryl-or heteroaryl-methyl)beta-piperidinopropanoic acid compounds as ORL 1-receptor antagonistsInfo
- Publication number
- ZA200710341B ZA200710341B ZA200710341A ZA200710341A ZA200710341B ZA 200710341 B ZA200710341 B ZA 200710341B ZA 200710341 A ZA200710341 A ZA 200710341A ZA 200710341 A ZA200710341 A ZA 200710341A ZA 200710341 B ZA200710341 B ZA 200710341B
- Authority
- ZA
- South Africa
- Prior art keywords
- orl
- heteroaryl
- beta
- aryl
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69190505P | 2005-06-17 | 2005-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200710341B true ZA200710341B (en) | 2008-10-29 |
Family
ID=37075616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200710341A ZA200710341B (en) | 2005-06-17 | 2007-11-28 | Alpha-(aryl-or heteroaryl-methyl)beta-piperidinopropanoic acid compounds as ORL 1-receptor antagonists |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080207665A1 (zh) |
EP (1) | EP1896479A1 (zh) |
JP (1) | JP2008543826A (zh) |
KR (1) | KR20080012977A (zh) |
CN (1) | CN101233139A (zh) |
AU (1) | AU2006257273A1 (zh) |
CA (1) | CA2611030A1 (zh) |
IL (1) | IL187654A0 (zh) |
MX (1) | MX2007016215A (zh) |
NO (1) | NO20080285L (zh) |
WO (1) | WO2006134485A1 (zh) |
ZA (1) | ZA200710341B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
FI3769765T3 (fi) * | 2018-03-19 | 2024-05-15 | Taiho Pharmaceutical Co Ltd | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus |
TW202237143A (zh) | 2020-12-10 | 2022-10-01 | 南韓商Lg化學股份有限公司 | 酸(Boronic Acid)化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166209A (en) * | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
US20030078278A1 (en) * | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
EP1732928A2 (en) * | 2004-03-29 | 2006-12-20 | Pfizer, Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
-
2006
- 2006-06-08 AU AU2006257273A patent/AU2006257273A1/en not_active Abandoned
- 2006-06-08 US US11/917,210 patent/US20080207665A1/en not_active Abandoned
- 2006-06-08 KR KR1020077029447A patent/KR20080012977A/ko not_active Application Discontinuation
- 2006-06-08 CN CNA2006800217055A patent/CN101233139A/zh active Pending
- 2006-06-08 EP EP06765538A patent/EP1896479A1/en not_active Withdrawn
- 2006-06-08 JP JP2008516443A patent/JP2008543826A/ja active Pending
- 2006-06-08 WO PCT/IB2006/001624 patent/WO2006134485A1/en active Application Filing
- 2006-06-08 MX MX2007016215A patent/MX2007016215A/es unknown
- 2006-06-08 CA CA002611030A patent/CA2611030A1/en not_active Abandoned
-
2007
- 2007-11-26 IL IL187654A patent/IL187654A0/en unknown
- 2007-11-28 ZA ZA200710341A patent/ZA200710341B/xx unknown
-
2008
- 2008-01-15 NO NO20080285A patent/NO20080285L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007016215A (es) | 2008-03-07 |
NO20080285L (no) | 2008-03-10 |
IL187654A0 (en) | 2008-08-07 |
KR20080012977A (ko) | 2008-02-12 |
WO2006134485A1 (en) | 2006-12-21 |
US20080207665A1 (en) | 2008-08-28 |
AU2006257273A1 (en) | 2006-12-21 |
JP2008543826A (ja) | 2008-12-04 |
AU2006257273A8 (en) | 2010-01-07 |
CN101233139A (zh) | 2008-07-30 |
EP1896479A1 (en) | 2008-03-12 |
CA2611030A1 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2395A (en) | New composition containing quinoline compounds. | |
IL185399A0 (en) | Pyridyl acetic acid compounds | |
EP1758458A4 (en) | COMPOSITIONS CONTAINING OPIOIDANT AGONISTS | |
IL179888A0 (en) | Compounds as ccr5 antagonists | |
EP1940412A4 (en) | NEW OPIOID ANTAGONISTS | |
IL192242A0 (en) | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides | |
HK1113927A1 (en) | Substituted triazole derivatives as oxytocin antagonists | |
EP1911738A4 (en) | PHENOXYALKANSÄUREVERBINDUNG | |
EP1850870A4 (en) | COMPOSITION FOR ADJUVANT CONTAINING POLY-GAMMA-GLUTAMIC ACID | |
IL185326A0 (en) | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | |
EP1945028A4 (en) | SUBSTITUTED NICOTINAMIDE COMPOUNDS | |
IL185327A0 (en) | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | |
ZA200806065B (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
ZA200710511B (en) | Alpha(aryl- or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL 1-receptor antagonists | |
EP1879563A4 (en) | NEW CHEMICAL COMPOUNDS | |
IL179912A0 (en) | Substituted diketopiperazines as oxytocin antagonists | |
ZA200803454B (en) | Piperazine derivatives useful as CCR5 antagonists | |
IL184737A (en) | Worm remedy | |
AP2007004227A0 (en) | Novel compounds as GLP-1 agonists | |
ZA200710341B (en) | Alpha-(aryl-or heteroaryl-methyl)beta-piperidinopropanoic acid compounds as ORL 1-receptor antagonists | |
IL195027A0 (en) | Constrained compounds as cgrp-receptor antagonists | |
ZA200809205B (en) | Constrained compounds as CGRP-receptor antagonists | |
EP1750722A4 (en) | NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS | |
GB0427403D0 (en) | Novel compounds I | |
EP1885362A4 (en) | NEW CHEMICAL COMPOUNDS |